Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that long-term use of difluprednate ophthalmic emulsion in dogs can lead to HPA axis suppression and potentially cause iatrogenic hyperadrenocorticism, with localized alopecia suspected due to dermal absorption.

This study found that in participants with notalgia paresthetica, 8 weeks of treatment with difelikefalin significantly improved itch intensity and increased the rate of strict complete response compared to placebo, starting as early as week 3.

This study found that D-004, a lipid extract from royal palm fruit, has a moderate antidepressant effect in mice, which may help treat depressive symptoms in patients with benign prostatic hyperplasia.

This study found that the antiviral drug daclatasvir significantly improved fibrosis and quality of life in a mouse model of recessive dystrophic epidermolysis bullosa, suggesting potential for treating this and other fibrotic diseases.

This review concluded that corticosteroids improve muscle strength and function in boys with Duchenne muscular dystrophy over short-term periods, but evidence on prolonging walking ability remains insufficient, and side effects are common.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Deuruxolitinib is generally safe for treating alopecia areata.

In this study, an ultra-low dose combination of estradiol and dydrogesterone significantly reduced hot flushes and improved health-related quality of life among a multi-ethnic population of postmenopausal women, with no notable difference in serious adverse events compared to placebo.

This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.

This study found that a transdermal delivery system using 3% azone and P407 gel may enhance the skin permeation of doxazosin and finasteride for treating benign prostatic hyperplasia.

This study found that deuruxolitinib may effectively improve hair regrowth and patient satisfaction in moderate to severe alopecia areata, but careful monitoring is needed due to manageable side effects and concerns about long-term safety.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

This study developed a consensus document to guide danazol discontinuation in hereditary angioedema patients, enhancing the standardization and safety of treatment protocols.

This study found that once-daily oxiconazole cream effectively treats tinea infections, achieving at least 80% cure rates, and shows comparable efficacy to other antifungal creams with similar tolerability.

Dovobet ointment used overnight effectively reduces scalp psoriasis severity and itch.

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

This study identified diltiazem, a calcium channel blocker for hypertension, as a promising repurposed treatment for influenza, enhancing antiviral efficacy when combined with oseltamivir.

This study found that both finasteride and dutasteride significantly reduced L-DOPA-induced dyskinesia in a rat model of Parkinson's disease, with dutasteride showing greater effectiveness at lower doses.

This study found that dexamethasone nanocrystals significantly increased drug penetration into skin compared to a traditional cream formulation, suggesting potential benefits for treating inflammatory skin conditions.

This study found that dexamethasone effectively suppressed DHEAS levels in women with elevated levels using much lower doses than previously thought, without significant adverse effects.

This study reviewed the pharmacological properties of fesoterodine and found that its ability to effectively treat overactive bladder, especially in the elderly, is likely due to its specific properties, including its receptor affinity, blood-brain barrier penetration, metabolic conversion, and extended-release formulation.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.